linjc16/ctgov huggingface dataset:
Effects of Different Ventilatory Strategy During Bronchoscopy

Study Overview
=================
Brief Summary
-----------------
The execution of diagnostic-therapeutic investigations by bronchial endoscopy can expose the patient to hypoxemia. For this reason, oxygen therapy is administered at low or high flows during the course of bronchoscopic procedures. Our study aim was to evaluate the efficacy and complications of High-flow nasal oxygen (HFNO) via Supraglottic jet oxygenation and ventilation (SJOV)during flexible bronchoscopy.

Official Title
-----------------
Effects of Different Ventilatory Strategy During Bronchoscopy

Conditions
-----------------
Bronchoscopy

Intervention / Treatment
-----------------
* Device: Conventional Oxygen Therapy
* Device: High-flow nasal oxygen
* Device: Supraglottic jet oxygenation and ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: need for bronchial endoscopy Exclusion Criteria: life-threatening cardiac aritmia or acute miocardical infarction within 6 weeks need for invasive or non invasive ventilation presence of pneumothorax or pulmonary enphisema or bullae recent (within 1 week) thoracic surgery presence of chest burns presence of tracheostomy pregnancy nasal or nasopharyngeal diseases dementia lack of consent or its withdrawal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group I<br>Conventional Oxygen Therapy | Device: Conventional Oxygen Therapy<br>* Conventional Oxygen Therapy will be administered through Nasal catheter<br>|
| Experimental: Group II<br>High-flow nasal oxygen | Device: High-flow nasal oxygen<br>* High Flow Nasal Cannula will be administered<br>|
| Experimental: Group III<br>Supraglottic jet oxygenation and ventilation | Device: Supraglottic jet oxygenation and ventilation<br>* Nasal jet tube will be administered<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare the intraoperative oxygenation. | The study will monitor the SpO2， heart rate(HR) and mean arterial pressure (MAP) during the procedure. | During bronchoscopy, an average of 0.5 hour. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial blood gases | Arterial blood gas analysis will be monitored at end of of procedure. | At end of of bronchoscopy,an average of 0.5 hour after bronchoscope insertion. | 
| Assess the regional ventilation distribution by Electrical impedance tomography . | Measurements will be done after bronchoscope insertion and at the end of the procedure. | During bronchoscopy, an average of 0.5 hour. |
High Power Short Duration Ablation Compared to Moderate Power Long Duration Ablation for Pulmonary Vein Isolation

Study Overview
=================
Brief Summary
-----------------
High Power Short Duration Ablation Compared to Moderate Power Long Duration Ablation for Pulmonary Vein Isolation: safety and acute procedural outcome

Official Title
-----------------
High Power Short Duration Ablation Compared to Moderate Power Long Duration Ablation for Pulmonary Vein Isolation: Safety and Acute Procedural Outcome

Conditions
-----------------
Paroxysmal Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: High power short duration ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptomatic, documented, drug-resistent paroxysmal atrial fibrillation effective oral anticoagulation Exclusion Criteria: any prior left atrial ablation procedure presence of left atrial thrombus secondary atrial fibrillation due to electrolyte imbalance or thyroid disease any prior oesophageal or gastric surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High power short duration ablation<br> | Procedure: High power short duration ablation<br>* Pulmonary vein isolation by high power short duration radiofrequency catheter ablation<br>|
| Moderate power long duration ablation<br> | Procedure: High power short duration ablation<br>* Pulmonary vein isolation by high power short duration radiofrequency catheter ablation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of reconnected pulmonary veins 20 minutes after ablation in comparison of both ablation groups |  | Acute endpoint | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first documented recurrence of atrial fibrillation after a 6-week blanking period. |  | 12 months after ablation |
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department

Study Overview
=================
Brief Summary
-----------------
Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE is defined as physical swelling of the deep skin layers or mucous membranes due to increased vascular permeability and leakage of fluid into the interstitial space caused while taking an ACEi

Detailed Description
-----------------
Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE most commonly affects the lips, mouth, face, upper airway, and less commonly the gastrointestinal tract. This condition may lead to life-threatening airway compromise which would require emergent intubation. Currently, strong evidence is lacking to help guide management of ACEi-AE in the emergency department (ED).

Official Title
-----------------
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department

Conditions
-----------------
Angioedema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be ≥ 18 years old, be diagnosed with suspected ACEi-AE (with ACEi use). ACEi use is defined as patient-reported use or evidence indicating use listed in the chart. Exclusion Criteria: Patients will be excluded if they have an allergy to TXA or any components of the formulation, present with an urticaria, have a personal or family history of hereditary angioedema, or received TXA administration in another department besides the ED.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospective Cohort<br>ED at MCMC for ACEi-AE with TXA | |
| Retrospective Chort<br>ED at MCMC for ACEi-AE without TXA | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intubation patients | Proportion of patients who required intubation during their hospital length of stay. | 2 weeks | 
| Admission proportion | The proportion of admissions to the ICU or another floor within MCMC Time to hospital discharge. | 2 weeks |
Elastography and Treatment of Lymphoma

Study Overview
=================
Brief Summary
-----------------
To determine accuracy of elastography in assessment of superficial lymph nodes response to treatment in cases of lymphoma.

Detailed Description
-----------------
Lymphomas are a heterogeneous group of malignancies that arise from the clonal proliferation of lymphocytes. It represents approximately 5% of malignancies. Overall survival is estimated to be 72%. (1) Lymphomas are broadly classified into Hodgkin lymphoma (HL) (10%) and Non-Hodgkin lymphoma (NHL) (90%). HL is further classified into classical and non-classical types and NHL into B-cell, T-cell and natural killer (NK) cell types. Diagnosis of lymphoma is confirmed by histopathology (FNAC, True-cut or excisional biopsy).(2) The standard treatment of lymphoma is chemotherapy and radiotherapy. The modalities used for staging and follow up of lymphoma are: Computed Tomography (CT) chest, abdomen and pelvis. Positron Emission Tomography (PET/CT). Whole body Magnetic Resonance Imaging (MRI).(3) Sonoelastography is a new technique that depends on the elastic properties of soft tissues, with the idea of malignant lesions being stiffer than benign or normal tissue. It may have a dependable role in evaluation of therapeutic response in patients with lymphoma and can be used for follow up, the same way it has been used in different parts of the body, such as the breast, and thyroid. To the best of our knowledge, there are few studies concerning the role of elastography in the field of lymphoma disease.(4)

Official Title
-----------------
The Role of Sonoelastography in Evaluation of Therapeutic Response in Patients With Lymphoma.

Conditions
-----------------
Elastography, Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who are histopathologically proven as lymphoma, not receive treatment and have superficial lymphadenopathy. Exclusion Criteria: 1-Lymphoma without superficial lymph nodes. 2-patients under treatment.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine accuracy of elastography in assessment of superficial lymph nodes response to treatment in cases of lymphoma. | Sonoelastography is a new technique that depends on the elastic properties of soft tissues, with the idea of malignant lesions being stiffer than benign or normal tissue. It may have a dependable role in evaluation of therapeutic response in patients with lymphoma and can be used for follow up, the same way it has been used in different parts of the body, such as the breast, and thyroid. To the best of our knowledge, there are few studies concerning the role of elastography in the field of lymphoma disease. | Average three years |
Concomitant Posterior Colporrhaphy on Bowel Functions in Pelvic Organ Prolapse Repair

Study Overview
=================
Brief Summary
-----------------
Compare the changes of preoperative and postoperative posterior colporrhaphy.

Detailed Description
-----------------
Introduction: Concomitant posterior colporrhaphy was frequently used during pelvic organ prolapse repair. Objectives: To evaluate the correlation between the presence of bowel symptoms and s rectocele severity and elucidate the impact of posterior colporrhaphy on bowel functions. Methods: Medical records of all consecutive women who received concomitant posterior colporrhaphy for their pelvic organ prolapse repairs were reviewed. In general, all women were requested to answer bowel incontinence assessment questionnaires before and after surgery. Possible results: Differences in rectocele severities between the presence or absence of fecal incontinence, flatus incontinence, constipation, diarrhea or sensation of residual stool will be shown.

Official Title
-----------------
The Impact of Concomitant Posterior Colporrhaphy on Bowel Functions in Women Who Received Pelvic Organ Prolapse Repair

Conditions
-----------------
Prolapse; Female

Intervention / Treatment
-----------------
* Procedure: posterior colporrhaphy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with pelvic organ prolapse planned to receive concomitant posterior colporrhaphy Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Posterior colporrhaphy<br>Medical records of women received concomitant posterior colporrhaphy for their pelvic organ prolapse repairs. Comparison will be made to compare preoperative and postoperative conditions. | Procedure: posterior colporrhaphy<br>* posterior colporrhaphy for rectocele.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with fecal incontinence | Number of participants present the symptom | before the operation, postoperative one month and three months. | 
| Number of participants with flatus | Number of patients present the symptom | before the operation, postoperative one month and three months. | 
| Number of participants with constipation | Number of patients present the symptom | before the operation, postoperative one month and three months. | 
| Number of participants with diarrhea | Number of patients present the symptom | before the operation, postoperative one month and three months. | 
| Number of participants with sensation of residual stool | Number of patients present the symptom | before the operation, postoperative one month and three months. |
Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women

Study Overview
=================
Brief Summary
-----------------
Consecutive obstetric patients attending routine antenatal visits were enrolled in this ongoing registry. A standardized 2D transthoracic echocardiogram (TTE) protocol was employed. Ejection fraction (EF) was quantified using biplane Simpson's method.

Detailed Description
-----------------
Consecutive obstetric patients attending routine antenatal visits were enrolled in this ongoing registry. A standardized 2D transthoracic echocardiogram (TTE) protocol was employed, including parasternal long and short, apical 4- and 2-chamber views. Continuous wave and pulse wave Doppler were used to assess left ventricular outflow tract (LVOT) gradients. Left ventricular (LV) function was quantified using biplane Simpson's method and visually assessed by two independent readers. Patients with significant valve disease or congenital heart disease underwent complete TTE. Those diagnosed with LV dysfunction or other cardiovascular diseases (CVD) were referred to the Cardio-Obstetrics clinic for further management and long-term follow-up.

Official Title
-----------------
Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women

Conditions
-----------------
Cardiovascular Diseases in Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obstetric patients attending routine antenatal visits Exclusion Criteria: Patients refused to give consent for echocardiography or participation in the study
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants found to have abnormal left ventricular function | Prevalence of Left ventricular dysfunction (Ejection Fraction<55%) | At the time of screening echocardiogram | 
| Number of participants found to have abnormal heart valve function | Structural heart abnormalities (valvular heart lesions classified as mild, moderate and severe) | At the time of screening echocardiogram | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants found to have adverse Maternal outcomes | Maternal Mortality, Cardiogenic shock | At the time of delivery | 
| Number of participants found to have adverse Fetal outcomes | Infant Mortality, Infant birth weight (kg) | At the time of delivery |
Low Level Laser Therapy Applied in Orthodontic Tooth Movement

Study Overview
=================
Brief Summary
-----------------
Currently, orthodontic treatment takes 2-3 years.. If we accelerate tooth movement by low energy laser therapy, we could reduce treatment time. Low Level Laser Therapy(LLLT) applied in Orthodontic Tooth Movement, which stimulates formation of osteoclast-like cells expression in vitro. Osteoclast can be served as an index for tooth movement. Increasing the number of osteoclast will increase bone formation and tooth movement. We plan to find a useful clinical protocol to improve the efficiency of orthodontic tooth movement. Test low energy laser in vitro. Find an effective wavelength and irradiation time to stimulate formation of osteoclast. Develop an useful protocol that clinical orthodontist could follow and reduce orthodontic treatment time.

Official Title
-----------------
Low Level Laser Therapy Applied in Orthodontic Tooth Movement

Conditions
-----------------
Orthodontic Appliance Complication

Intervention / Treatment
-----------------
* Device: Low Level Laser Therapy
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with good oral hygiene 18 years old Patients who required bilateral canine retraction into the extracted premolar Exclusion Criteria: Serious medical history Poor oral hygiene Previous orthodontic treatment Orthognathic surgery or syndromic patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: with LLLT<br> | Device: Low Level Laser Therapy<br>* Low level laser therapy could provide energy to trigger cell differentiation.<br>|
| Placebo Comparator: without LLLT<br> | Other: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Orthodontic tooth movement | the distance between canine and premolar | 1-6month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bone density after Orthodontic tooth movement | bone density change around canine | 1-6month |
Unveiling Patient Experiences in Testicular Cancer Clinical Trials

Study Overview
=================
Brief Summary
-----------------
Clinical research participation has historically been heavily biased toward specific demographics. Several people will be invited to enroll in this study so that it may collect a variety of data about testicular cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. People with testicular cancer who are invited to take part in medical research will benefit from the analysis of the data.

Official Title
-----------------
Patient Perspectives in Testicular Cancer Clinical Trials: Insights Into Participating in Studies for Testicular Cancer

Conditions
-----------------
Testicular Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed Diagnosis of testicular cancer No prior treatment for testicular cancer Exclusion Criteria: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial Enrolled in another research study Inability to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of testicular cancer patients who decide to enroll in a clinical trial |  | 3 months | 
| Rate of testicular cancer patients who remain in a clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
testicular cancer
Blood Pressure Monitor Clinical Test (Cuff Range: 13.5cm-19.5cm）

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to verify the accuracy of the blood pressure cuffs with blood pressure monitor device. Cuff circumference is 13.5cm-19.5cm.

Official Title
-----------------
Blood Pressure Monitor#Model#KD-7920#Clinical Test

Conditions
-----------------
Blood Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal blood pressure and hypertensive patients over 12 years old. Exclusion Criteria: Patients with serious arrhythmias or a high frequency of arrhythmias Pregnant woman Other investigators believe that it is not suitable to participate in this clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subject use both KD-7920 Wrist Automatic Electronic BPM and mercury sphygmomanometers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood pressure monitor accuracy | All the test results of the electronic blood pressure monitor with the cuff is within the accuracy creteria, with the merury sphygmomanometer as control | 30 minutes |